Results 151 to 160 of about 1,105,613 (399)

Discovery of the Principal Cystic Fibrosis Mutation (F508del) in Ancient DNA from Iron Age Europeans [PDF]

, 2007
The most common, life-threatening autosomal recessive disease of Europeans and Euro-Americans, cystic fibrosis (CF), occurs predominately in patients with the F508del mutation.1 Although F508del is currently detectable as a single allele in 1/30-1/40 ...
Cedric Le Marechal, Claude Ferec, Malika Siker, Maria Teschler-Nicola, Philip Farrell   +4 more
core   +1 more source

Development of Novel Anticancer Pyrazolopyrimidinones Targeting Glioblastoma

ChemMedChem, EarlyView.
Pyrazolo[1,5‐α]pyrimidinone derivatives exhibit selective cytotoxicity towards glioblastoma (GBM) cells over noncancerous cells. Structure–activity relationship studies identifies a lead compound with significant cytotoxicity activity, inducing apoptosis and necrosis in GBM cells, without affecting noncancerous cells. This demonstrates the potential of
Kate Byrne, Natalia Bednarz, Ciara McEvoy, John C. Stephens, James F. Curtin, Gemma K. Kinsella   +5 more
wiley   +1 more source

Cystic fibrosis of the pancreas: structural changes in peripheral airways [PDF]

, 1968
John R. Esterly, Ella H. Oppenheimer
openalex   +1 more source

Recent Insights in Multi‐Target Drugs in Pharmacology and Medicinal Chemistry

ChemMedChem, EarlyView.
This review highlights the rationale behind multitarget drug design as a promising approach to address diseases with complex etiologies. By combining pharmacophore features from different single‐target drugs, multitarget compounds can interact with multiple biological targets simultaneously.
Sadık Hüseyin Cemali, Samet Poyraz, Samet Belveren, Senanur Taş, Mehmet Ali Tamer, Naciye Yaktubay Döndaş, H. Ali Döndaş, Jose Miguel Sansano   +7 more
wiley   +1 more source

CFTR modulators response of S737F and T465N CFTR variants on patient-derived rectal organoids

Orphanet Journal of Rare Diseases
Background Predictions based on patient-derived materials of CFTR modulators efficacy have been performed lately in patient-derived cells, extending FDA-approved drugs for CF patients harboring rare variants.
Karina Kleinfelder, Paola Melotti, Anca Manuela Hristodor, Cristina Fevola, Giovanni Taccetti, Vito Terlizzi, Claudio Sorio   +6 more
doaj   +1 more source

Considerations in Transition of Pediatric Neurology Patients to Adult Care

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Background Transition refers to the planned, coordinated movement of adolescents from the child‐ and family‐centered environment of pediatric care to the adult healthcare system. A well‐structured transition process is essential for ensuring adolescents with chronic health conditions continue to thrive in young adulthood.
Asif Doja, Katherine Muir, Megan E. Harrison, Sarah Healy, Ashley Vandermorris, Alene Toulany   +5 more
wiley   +1 more source

Detection of cytokines in nasal lavage samples of patients with cystic fibrosis: comparison of two different cytokine detection assays

BMC Pulmonary Medicine
Background Cystic fibrosis (CF) is a genetic multisystem disorder. Inflammatory processes, which presumably begin early in infancy, play a crucial role in the progression of the disease. The detection of inflammatory biomarkers, especially in the airways,
Teresa Fuchs, Manuela Zlamy, Thomas Zöggeler, Dorothea Appelt, Katharina Niedermayr, Anja Siedl, Verena Gasser, Johannes Eder, Helmut Ellemunter   +8 more
doaj   +1 more source

Side-effects to antibiotics in cystic fibrosis: dental changes in relation to antibiotic administration. [PDF]

, 1967
J.N. Swallow, Jordan D. Haller, William F. Young   +2 more
openalex   +1 more source

The future of cystic fibrosis care: a global perspective.

The Lancet Respiratory Medicine, 2020
S. Bell, M. Mall, H. Gutierrez, M. Macek, S. Madge, J. Davies, P. Burgel, E. Tullis, C. Castaños, C. Castellani, C. Byrnes, F. Cathcart, S. H. Chotirmall, R. Cosgriff, I. Eichler, I. Fajac, C. Goss, P. Dřevínek, P. Farrell, A. Gravelle, T. Havermans, N. Mayer-Hamblett, N. Kashirskaya, E. Kerem, J. Mathew, E. McKone, L. Naehrlich, S. Nasr, G. Oates, C. O’Neill, Ulrike Pypops, K. Raraigh, S. Rowe, K. Southern, S. Sivam, A. Stephenson, M. Zampoli, F. Ratjen   +37 more
semanticscholar   +1 more source

Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity

Clinical Pharmacology &Therapeutics, EarlyView.
Polymyxins are used against highly resistant Gram‐negative pathogens, and nephrotoxicity (acute kidney injury, AKI) is the major dose‐limiting adverse effect. We aimed to develop a well‐informed population pharmacokinetic/toxicodynamic (PK/TD) model using the largest polymyxin B‐treated critically ill patient population studied to inform polymyxin B ...
Patrick O. Hanafin, Ramya Mahadevan, Gauri G. Rao, Alexandre P. Zavascki, Ana Maria Sandri, Andrea Kwa, Marc H. Scheetz, Christine J. Kubin, Jayesh Shah, Benjamin P.Z. Cherng, Michael T. Yin, Jiping Wang, Lu Wang, David P. Calfee, Maureen Bolon, Anthony W. Purcell, Roger L. Nation, Jason M. Pogue, Jian Li, Keith S. Kaye   +19 more
wiley   +1 more source